Stock Track | Erasca Soars 8.78% Intraday on Positive Clinical Trial Updates and Corporate Pipeline Presentation

Stock Track

Apr 30

Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.

The sharp price increase followed the company's publication of a corporate presentation detailing its RAS/MAPK cancer drug pipeline. Erasca highlighted positive early clinical data from its AURORAS-1 Phase 1/1b trial for ERAS-0015, a Pan-RAS molecular glue, with responses first observed at the 8 mg once daily dose. As of January 7, 2026, the trial reported ongoing responses including 2 confirmed partial responses and 1 unconfirmed partial response.

Investors were also encouraged by the company's robust financial position, which includes $342 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and an oversubscribed equity financing that closed in January 2026. The company anticipates its cash runway will extend into the second half of 2028, providing substantial funding for its clinical development programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1156473634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156473634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156473634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156473634","market":"us","top_or_hot":-1,"title":"Stock Track | Erasca Soars 8.78% Intraday on Positive Clinical Trial Updates and Corporate Pipeline Presentation","media":"Stock Track","content":"<p>Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.</p><p>The sharp price increase followed the company's publication of a corporate presentation detailing its RAS/MAPK cancer drug pipeline. Erasca highlighted positive early clinical data from its AURORAS-1 Phase 1/1b trial for ERAS-0015, a Pan-RAS molecular glue, with responses first observed at the 8 mg once daily dose. As of January 7, 2026, the trial reported ongoing responses including 2 confirmed partial responses and 1 unconfirmed partial response.</p><p>Investors were also encouraged by the company's robust financial position, which includes $342 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and an oversubscribed equity financing that closed in January 2026. The company anticipates its cash runway will extend into the second half of 2028, providing substantial funding for its clinical development programs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Erasca Soars 8.78% Intraday on Positive Clinical Trial Updates and Corporate Pipeline Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Erasca Soars 8.78% Intraday on Positive Clinical Trial Updates and Corporate Pipeline Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.</p><p>The sharp price increase followed the company's publication of a corporate presentation detailing its RAS/MAPK cancer drug pipeline. Erasca highlighted positive early clinical data from its AURORAS-1 Phase 1/1b trial for ERAS-0015, a Pan-RAS molecular glue, with responses first observed at the 8 mg once daily dose. As of January 7, 2026, the trial reported ongoing responses including 2 confirmed partial responses and 1 unconfirmed partial response.</p><p>Investors were also encouraged by the company's robust financial position, which includes $342 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and an oversubscribed equity financing that closed in January 2026. The company anticipates its cash runway will extend into the second half of 2028, providing substantial funding for its clinical development programs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"","article_id":"1156473634","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156473634","pubTimestamp":1777563182,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.The sharp price increase followed the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC."},"translate_title":"个股追踪|Erasca盘中大涨8.78%，因积极的临床试验更新和公司管线展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1},"content_text":"Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.The sharp price increase followed the company's publication of a corporate presentation detailing its RAS/MAPK cancer drug pipeline. Erasca highlighted positive early clinical data from its AURORAS-1 Phase 1/1b trial for ERAS-0015, a Pan-RAS molecular glue, with responses first observed at the 8 mg once daily dose. As of January 7, 2026, the trial reported ongoing responses including 2 confirmed partial responses and 1 unconfirmed partial response.Investors were also encouraged by the company's robust financial position, which includes $342 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and an oversubscribed equity financing that closed in January 2026. The company anticipates its cash runway will extend into the second half of 2028, providing substantial funding for its clinical development programs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}